CDT (CDT Equity) Total Liabilities: $12.82 Mil (As of Dec. 2025)


CDT CDT Equity Inc CDT
10 GF Score
Price $0.64
! 5 Warning Signs
View Full Analysis

What is CDT Equity Total Liabilities?

CDT Equity CDT -10.81% 10 Total Liabilities is $12.82 Mil as of Dec. 2025. GuruFocus rates CDT with a GF Score™ of 10/100. The stock has 5 warning signs investors should review.

CDT Equity's Total Liabilities for the quarter that ended in Dec. 2025 was $12.82 Mil.

CDT Equity's quarterly Total Liabilities declined from Jun. 2025 ($4.46 Mil) to Sep. 2025 ($4.27 Mil) but then increased from Sep. 2025 ($4.27 Mil) to Dec. 2025 ($12.82 Mil).

CDT Equity's annual Total Liabilities increased from Dec. 2023 ($7.68 Mil) to Dec. 2024 ($10.99 Mil) and increased from Dec. 2024 ($10.99 Mil) to Dec. 2025 ($12.82 Mil).

CDT Equity Total Liabilities Historical Data

* Premium members only.

The historical data trend for CDT Equity's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CDT Equity Total Liabilities Chart

CDT Equity Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
5.94 10.09 7.68 10.99 12.82

CDT Equity Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.99 4.63 4.46 4.27 12.82
CDT
10GF Score
CDT Equity Inc CDT
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CDT Equity Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

CDT Equity's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=12.82+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=12.82

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=5.65--7.17
=12.82

CDT Equity's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=12.82+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=12.82

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=5.65--7.17
=12.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $12.82 Mil mean?
CDT Equity (CDT) has a Total Liabilities of $12.82 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for CDT Equity and its competitors.
Is CDT Equity's Total Liabilities too high?
CDT Equity's current Total Liabilities is $12.82 Mil. Overall, CDT Equity has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does CDT Equity's Total Liabilities compare to PULM and ADIL?
CDT Equity's Total Liabilities of $12.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for CDT Equity and its competitors. CDT Equity's current Total Liabilities is $12.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CDT Equity stock overvalued right now?
CDT Equity (CDT) has a current Total Liabilities of $12.82 Mil. The current Total Liabilities is $12.82 Mil. CDT Equity's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For CDT Equity (CDT), the current Total Liabilities is $12.82 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CDT Equity Business Description

Address 4581 Tamiami Trail North, Suite 200, Naples, FL, USA, 34103
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
10GF Score

Get the complete analysis for CDT

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.64
Price